6,527 Shares in Cencora, Inc. $COR Acquired by Passumpsic Savings Bank

Passumpsic Savings Bank purchased a new position in shares of Cencora, Inc. (NYSE:COR) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 6,527 shares of the company’s stock, valued at approximately $2,204,000.

Several other institutional investors have also made changes to their positions in COR. Oakworth Capital Inc. acquired a new stake in shares of Cencora during the fourth quarter worth approximately $26,000. Elyxium Wealth LLC acquired a new stake in shares of Cencora during the fourth quarter worth approximately $27,000. Archer Investment Corp boosted its holdings in shares of Cencora by 134.3% during the fourth quarter. Archer Investment Corp now owns 82 shares of the company’s stock worth $28,000 after purchasing an additional 47 shares during the period. IAG Wealth Partners LLC acquired a new stake in shares of Cencora during the third quarter worth approximately $30,000. Finally, Cloud Capital Management LLC acquired a new stake in shares of Cencora during the third quarter worth approximately $31,000. 97.52% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

COR has been the subject of several research reports. Citigroup decreased their price target on shares of Cencora from $405.00 to $355.00 and set a “buy” rating for the company in a report on Thursday, May 7th. William Blair initiated coverage on shares of Cencora in a report on Tuesday, April 28th. They set a “market perform” rating for the company. Weiss Ratings reiterated a “buy (b)” rating on shares of Cencora in a research note on Monday, May 4th. JPMorgan Chase & Co. lifted their target price on shares of Cencora from $417.00 to $419.00 and gave the company an “overweight” rating in a research note on Tuesday, February 10th. Finally, Barclays lifted their target price on shares of Cencora from $400.00 to $425.00 and gave the company an “overweight” rating in a research note on Friday, February 13th. Twelve research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to MarketBeat, Cencora presently has a consensus rating of “Moderate Buy” and a consensus price target of $380.25.

Cencora Stock Down 0.3%

Shares of NYSE:COR opened at $256.96 on Monday. Cencora, Inc. has a 52 week low of $244.82 and a 52 week high of $377.54. The company has a debt-to-equity ratio of 3.40, a quick ratio of 0.59 and a current ratio of 0.95. The company’s fifty day moving average is $314.65 and its 200-day moving average is $339.24. The company has a market capitalization of $49.99 billion, a PE ratio of 19.71, a P/E/G ratio of 1.19 and a beta of 0.64.

Cencora (NYSE:COR) last issued its earnings results on Wednesday, May 6th. The company reported $4.75 EPS for the quarter, missing the consensus estimate of $4.82 by ($0.07). Cencora had a net margin of 0.78% and a return on equity of 135.20%. The firm had revenue of $78.36 billion during the quarter, compared to analyst estimates of $81.09 billion. During the same quarter in the prior year, the firm posted $4.42 EPS. The firm’s revenue for the quarter was up 3.9% on a year-over-year basis. Cencora has set its FY 2026 guidance at 17.650-17.900 EPS. Equities research analysts predict that Cencora, Inc. will post 17.76 earnings per share for the current fiscal year.

Cencora Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, June 1st. Stockholders of record on Friday, May 15th will be paid a $0.60 dividend. This represents a $2.40 annualized dividend and a dividend yield of 0.9%. The ex-dividend date is Friday, May 15th. Cencora’s payout ratio is currently 18.40%.

Cencora Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.